肝癌患者中RNF24的表达及临床价值

doi:10.3969/j.issn.1009-976X.2021.02.007

岭南现代临床外科 ›› 2021, Vol. 21 ›› Issue (02): 165-170.DOI: 10.3969/j.issn.1009-976X.2021.02.007

肝癌患者中RNF24的表达及临床价值

伍隽华¹, 陈云扬¹, 张鑫¹, 余杰雄¹, 崔恩铭¹, 张慧玲^2,*

1.江门市中心医院肝胆外科,广东江门529000;
2.中山大学附属第三医院肝胆外科,广州510630

通讯作者: *张慧玲,E-mail：1391999063@qq.com
基金资助:
2019年度江门市中心医院科研启动基金资助项目（D201902）; 2020年度江门市医疗卫生领域科技项目（2020YLA102）

Expression and clinical value of RNF24 in patients with hepatocellular carcinoma

WU Jun-hua¹, CHEN Yun-yang¹, ZHANG Xin¹, YU Jie-xiong¹, CUI En-ming¹, ZHANG Hui-ling²

1. Department of Hepatobiliary Surgery, Jiangmen Central Hospital, Jiangmen, Guangdong 529000, China;
2. Department of Hepatobiliary Surgery,The Third affiliated Hospital, Sun Yat-sen University, Guangzhou 510630, China

Received:2020-12-20 Online:2021-04-20 Published:2021-06-18
Contact: ZHANG Hui-ling, 1391999063@qq.com

摘要/Abstract

摘要： 目的探究RNF24基因在肝癌患者中的表达及其临床意义。方法利用UALCAN、HPA数据库分析RNF24在肝癌中的表达情况。利用TIMER数据库检测RNF24与免疫浸润的相关性及对患者生存的影响。利用Kaplan-Meier plotter工具分析RNF24不同表达水平对肝癌患者临床预后的影响。最后,通过Firebrowse下载肝癌患者临床数据,Cox回归分析预测RNF24对肝癌患者预后的价值。结果 UALCAN分析结果显示RNF24 mRNA在肝癌中表达量中位值为0.712（q1=0.376,q3=1.287）,显著高于正常肝组织中位值0.265（q1=0.17,q3=0.371）（P<0.01）。HPA 数据库分析显示,较相应正常肝组织而言,RNF24蛋白在肝癌组织中表达更高。同时,UALCAN分析结果提示肝癌中高表达的RNF24与患者临床分期、肿瘤分级密切相关。TIMER数据分析提示CD8⁺ T细胞,B细胞,树突状细胞,CD4⁺ T细胞,中性粒细胞和巨噬细胞的浸润水平与RNF24表达水平显著正相关。肿瘤分期、CD8⁺ T细胞、树突状细胞浸润水平以及RNF24表达都是肝癌患者预后的影响因素,而且RNF24表达是影响患者3年和5年生存率的独立危险因素。对从Firebrowse下载的205例具有完整信息的肝癌患者进行Cox回归分析,结果提示RNF24是肝癌患者预后的独立危险因素。结论 RNF24可作为预测肝癌患者预后的一种新型标记物。

关键词: RNF24, 肝癌, 预后, 生物信息学

Abstract: Objective To investigate the expression of RNF24 gene in patients with hepatocellular carcinoma （HCC） and its clinical significance. Methods Using UALCAN and HPA database to analyze the expression of RNF24 in HCC. TIMER database was used to detect the correlation between RNF24 and immune infiltration and its impact on patient survival. The Kaplan-Meier plotter tool was used to analyze the effects of different expression levels of RNF24 on the clinical prognosis of patients with HCC. Finally, download the clinical data of HCC patients through Firebrowse, and Cox regression analysis predicts the prognostic value of RNF24 for HCC patients. Results The results of UALCAN analysis showed that the median expression of RNF24 mRNA in HCC （Median, M） was 0.712 （q1=0.376, q3=1.287）, which was significantly higher than the median value of normal liver tissue of 0.265 （q1=0.17, q3=0.371）（P<0.01）. HPA database analysis shows that RNF24 protein is higher in HCC tissues than the corresponding normal liver tissues. TIMER analysis indicated that the infiltration level of CD8⁺ T cells, B cells, dendritic cells, CD4⁺ T cells, neutrophils and macrophages was significantly positively correlated with the expression level of RNF24. Tumor staging, CD8⁺ T cells, dendritic cell infiltration levels, and RNF24 expression are all risk factors for the prognosis of HCC patients. Cox regression analysis was performed in 205 HCC patients with complete information from Firebrowse, and the results showed that RNF24 is an independent risk factor for the prognosis of HCC patients. Conclusion RNF24 can be used as a new marker for predicting the prognosis of HCC patients.

Key words: RNF24, hepatocellular carcinoma, prognosis, bioinformatics

中图分类号:

R735.7

伍隽华, 陈云扬, 张鑫, 余杰雄, 崔恩铭, 张慧玲. 肝癌患者中RNF24的表达及临床价值[J]. 岭南现代临床外科, 2021, 21(02): 165-170.

WU Jun-hua, CHEN Yun-yang, ZHANG Xin, YU Jie-xiong, CUI En-ming, ZHANG Hui-ling. Expression and clinical value of RNF24 in patients with hepatocellular carcinoma[J]. Lingnan Modern Clinics In Surgery, 2021, 21(02): 165-170.

参考文献

[1] Yang JD, Hainaut P, Gores GJ, et al.A global view of hepatocellular carcinoma: trends, risk, prevention and management[J]. Nat Rev Gastroenterol Hepatol, 2019, 16(10): 589-604.
[2] Chengxi L, Rentao L, Wei Z.Progress in non-invasive detection of liver fibrosis[J]. Cancer Biol Med, 2018, 15(2): 124-136.
[3] Forner A, Reig M, Bruix J.Hepatocellular carcinoma[J]. Lancet, 2018, 391(10127): 1301-1314.
[4] Lussier MP, Lepage PK, Bousquet SM, et al.RNF24, a new TRPC interacting protein, causes the intracellular retention of TRPC[J]. Cell calcium, 2008, 43(5): 432-443.
[5] Chandrashekar DS, Bashel B, Balasubramanya SAH, et al.UALCAN: A Portal for Facilitating Tumor Subgroup Gene Expression and Survival Analyses[J]. Neoplasia, 2017, 19(8): 649-658.
[6] Asplund A, Edqvist PH, Schwenk JM, et al.Antibodies for profiling the human proteome-The Human Protein Atlas as a resource for cancer research[J]. Proteomics, 2012, 12(13): 2067-2077.
[7] Li T, Fan J, Wang B, et al.TIMER: A Web Server for Comprehensive Analysis of Tumor-Infiltrating Immune Cells[J]. Cancer Res, 2017, 77(21): e108-e110.
[8] Hou GX, Liu P, Yang J, et al.Mining expression and prognosis of topoisomerase isoforms in non-small-cell lung cancer by using Oncomine and Kaplan-Meier plotter[J]. PLoS One, 2017, 12(3): e0174515.
[9] Zhao C, Rispe C, Nabity PD.Secretory RING finger proteins function as effectors in a grapevine galling insect[J]. BMC genomics, 2019, 20(1): 923.
[10] Heuzé ML, Lamsoul I, Moog-Lutz C, et al.Ubiquitin-mediated proteasomal degradation in normal and malignant hematopoiesis[J]. Blood Cell Mol Dis, 2008, 40(2): 200-210.
[11] Azimi F, Scolyer RA, Rumcheva P, et al.Tumor-infiltrating lymphocyte grade is an independent predictor of sentinel lymph node status and survival in patients with cutaneous melanoma[J]. J Clin Oncol, 2012, 30(21): 2678-2683.
[12] Ohtani H.Focus on TILs: prognostic significance of tumor infiltrating lymphocytes in human colorectal cancer[J]. Cancer immun, 2007, 7: 4.

[1]	何冲, 周姝睿, 李雅晴, 陈少杰, 练国达, 陈尚祥, 黄开红. 胰腺癌预后相关铁死亡基因筛选及预后预测模型构建[J]. 岭南现代临床外科, 2022, 22(1): 14-23.
[2]	吴烨, 刘晓迪, 许燕妮, 罗葆明. 甲硫氨酸条件性缺乏增加瑞戈非尼对肝癌细胞药物敏感性的研究[J]. 岭南现代临床外科, 2022, 22(1): 24-29.
[3]	林杏仪, 田振烽, 潘乐乐, 苏铭昕, 陈茵婷. 基于GEO数据库的胰腺癌循环肿瘤细胞代谢通路及关键基因研究[J]. 岭南现代临床外科, 2022, 22(1): 34-41.
[4]	刘伟. 恶性脑胶质瘤单放和放化疗临床疗效5年随诊分析[J]. 岭南现代临床外科, 2022, 22(1): 89-93.
[5]	黄沾任, 宁金月, 李汉卿, 陈念平. 免疫联合靶向治疗在晚期肝癌转化治疗中的研究进展[J]. 岭南现代临床外科, 2022, 22(1): 110-114.
[6]	胡明超, 朱宝松. NDC1基因在结肠癌中诊断及预后价值的生物信息学分析：一项基于TCGA数据库的研究[J]. 岭南现代临床外科, 2021, 21(06): 598-602.
[7]	宋燕州, 康志龙, 苏一男, 张毅明, 赵新, 李志伟, 李伟. NEK7在原发性肝细胞肝癌患者中表达及其临床意义[J]. 岭南现代临床外科, 2021, 21(06): 608-613.
[8]	伍隽华, 谭慧敏, 左超海, 邝乃乐, 余杰雄, 陈云扬. TACE治疗预防肝癌术后复发的临床分析[J]. 岭南现代临床外科, 2021, 21(04): 397-404.
[9]	苏汝平, 李妮, 钟漓, 赵志. 腹腔镜肝切除联合脾动脉结扎术治疗肝癌合并门脉高压症的疗效分析[J]. 岭南现代临床外科, 2021, 21(04): 415-418.
[10]	王道笃, 赵其炯, 周志标, 何永越. 基于铁死亡相关基因构建肝细胞癌的预后模型[J]. 岭南现代临床外科, 2021, 21(04): 419-424.
[11]	王庆斌, 商昌珍, 陈亚进. 肝癌切除术后预后预测的研究进展[J]. 岭南现代临床外科, 2021, 21(04): 471-476.
[12]	何泳铸, 钱均霖, 叶少炜, 刘立文, 何坤, 黄锐钦, 罗启杰, 彭鹏, 胡泽民. 肝切除术后腹腔热灌注化疗治疗外生性破裂性肝癌的研究进展[J]. 岭南现代临床外科, 2021, 21(04): 477-481.
[13]	朱钊雯, 贾卫娟, 刘洁琼. Luminal型乳腺癌胞膜蛋白相关预后模型的构建与验证[J]. 岭南现代临床外科, 2021, 21(03): 281-286.
[14]	曾兵, 李锦宏, 蔡灿锋, 辛海洋, 曾军. ITGAV在结直肠癌中的表达及临床意义[J]. 岭南现代临床外科, 2021, 21(03): 309-312.
[15]	胡志鹏, 孙强, 胡泽民, 陈伟强. 基于增强CT的影像组学模型对BCLC B期肝细胞癌治疗方式选择的研究进展[J]. 岭南现代临床外科, 2021, 21(02): 233-238.

肝癌患者中RNF24的表达及临床价值

Expression and clinical value of RNF24 in patients with hepatocellular carcinoma

PDF

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics